This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
ANI Pharmaceuticals, Inc.
Drug Names(s): estradiol + testosterone gel
Description: LibiGel E/T is a estradiol + testosterone combination transdermal hormone therapy gel product.
Deal Structure: In June 2000, BioSante Pharmaceuticals signed an in-license agreement covering four hormone products for the treatment of testosterone deficiency in men and estrogen deficiency in women. The license agreement was signed with Permatec Technologie, AG of Switzerland. Under terms of the license agreement signed with Permatec, BioSante acquired exclusive marketing rights, with the right to grant sub-licenses, tothe three testosterone and estradiol products for all therapeutic indications in the U.S., Canada, Mexico, Israel, Australia, New Zealand, China, Malaysia, Indonesia and South Africa. BioSante will make an upfront payment, expects to fund the development of the products, make milestone payments and once regulatory approval to market is received, pay royalties on sales of the products.
In July 2000, Medi-Ject Corporation signed a Stock Purchase Agreement with Permatec Holding AG, a privately held drug delivery company located in Switzerland. Under the terms of the agreement,...See full deal structure in Biomedtracker
Partners: Antares Pharma, Inc.
LibiGel E/T News
Pink Sheet Weekly Trademark Review Feb. 24, 2015
Additional information available to subscribers only: